Linda Johnson
Gene therapy for hemophilia delayed until 2022 after FDA rejects one-time treatment, shocking doctors and scientists
U.S. regulators rejected [Biomarin’s] potentially game-changing hemophilia A gene therapy over concerns it might not really be a one-and-done lifetime ...
